Skip to Main Content

Paper Details

Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.
Cancer Chemother Pharmacol
0
2022

Datasets

Release 1.2